Dalton Pharma Services has received a three-year renewal and license amendment from Health Canada under the Cannabis Regulations. This amendment authorizes Dalton to sell cGMP cannabis derived products on a “business-to-business” basis to Federal License holders.   With its combined Health Canada cGMP and Cannabis licenses, Dalton is positioned to test, develop, produce, and supply cGMP cannabinoids to support the delivery and commercial success of medical cannabinoid products.   “This important...